Jupiros CV 20mg/75mg Tablet is a combination medication containing Rosuvastatin 20mg and Clopidogrel 75mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby decreasing the risk of atherosclerotic cardiovascular disease. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction and stroke. The combined formulation is particularly beneficial in patients with established coronary artery disease, recent acute coronary syndrome, or those undergoing percutaneous coronary intervention requiring dual therapy to prevent clot formation and progression of atherosclerosis. Jupiros CV should be administered once daily, preferably with or without food, as prescribed by a healthcare professional. Caution is advised in patients with hepatic impairment, bleeding disorders, or concomitant use of other anticoagulants. Regular monitoring of lipid profiles, liver function tests, and platelet counts is recommended to ensure therapeutic efficacy and safety. This combination therapy offers a convenient approach to comprehensive cardiovascular risk management.